This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
CAR T cell naïve and eligible to receive a CD19 CART-cell therapy
Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)
Diffuse large B-cell lymphoma (DLBCL)
Transformations of indolent B-cell lymphomas (excluding Richter's transformation)
Patients ineligible to receive CD19 CAR T-cell therapy
Primary CNS lymphoma
Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma, Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter's transformation)
Patients with prior history of malignancy, other than aggressive relapsed or refractory LBCL, unless the patient has been free of the disease for ≥ 2 years
Lyell Immunopharma, Inc.
Lead sponsor